Oppenheimer Invests in Pulse Biosciences Amid Institutional Interest Oppenheimer & Co. acquired 17,850 shares of Pulse Biosciences worth $311,000 during Q4. Other institutional investors, such as Charles Schwab and State Street, also increased their stakes. The company’s stock has shown volatility, with a 12-month range between $6.59 and $25.00, reflecting interest in its nsPFA technology.45